U.S. and Europe Atopic Dermatitis Market | Competitive Intelligence 2013 to 2017 | Forecast 2018 to 2024

 

 

U.S. and Europe Atopic Dermatitis Market report offers Market Size, Dynamics, Regional Market Share, Top Key Players, Latest trends, Growth factors, Industry Stats, Historic Market, Business Intelligence, Business Research Reports, Competitive Intelligence 2013 to 2017 and Forecast 2018 to 2024

 

The U.S. and Europe atopic dermatitis market is growing at a significant CAGR due to change in lifestyle, increase in atopic dermatitis population, and pollution and climatic changes. Growing prevalence of the food allergies and growing focus on new therapies are the key factors drive the U.S. and Europe atopic dermatitis market growth. Furthermore, increase in use of pharmacological products in developed countries. Increase in R&D expenditure to develop novel biologics, and improvement in healthcare expenditure might increase the growth of U.S. and Europe atopic dermatitis market over the forecast period. However, the challenge is time to be taken in drug adoption, high price and legal regulations might hamper the growth of U.S. and Europe atopic dermatitis market. Similarly, highly generalized nature of the atopic dermatitis market and lack of awareness on drug usage hinder the growth of U.S. and Europe atopic dermatitis market over the forecast period.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/u-s-and-europe-atopic-dermatitis-market/#ulp-njYIhocMn4o6wrda

 

 

The U.S. and Europe atopic dermatitis market is segmented on the basis of drug class, route of administration, and distribution channel

 

Based on drug class, U.S. and Europe atopic dermatitis market segmented into the following:

  • Immunosuppressants
  • PDE-4 Inhibitor
  • Antihistamines
  • Antibiotics
  • Biologic Therapy
  • Calcineurin Inhibitors
  • Corticosteroids
  • Emollients
  • Others

 

Based on the route of administration, U.S. and Europe atopic dermatitis market segmented into the following:

  • Injectable
  • Oral
  • Topical

 

Based on distribution channel, U.S. and Europe atopic dermatitis market segmented into the following:

  • Hospital pharmacies
  • Online pharmacies
  • Drug stores
  • Retail pharmacies

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/u-s-and-europe-atopic-dermatitis-market/#ulp-c654SbFYO64MsOhu

 

 

Various companies in atopic dermatitis market are focussed on partnerships with other companies to develop products. For instance, in October 2016, Allergan plc, successfully completed purchasing all outstanding shares of Vitae Pharmaceuticals, Inc., focussed on innovative development programs for dermatologic conditions. The completion of the Vitae acquisition added highly differentiated development compounds to Allergan’s medical dermatology pipeline. Furthermore, acquisitions take place in the atopic dermatitis space are accelerating the growth of the atopic dermatitis market. In July 2016, Leo Pharma acquired global license from AstraZeneca for monoclonal antibody tralokinumab that completed clinical phase 2b. In December 2016, Novartis acquired Ziarco Group Limited including ZPL389, an oral drug used in the treatment of atopic dermatitis. Launch of new products, new product approvals from U.S. and Europe regulatory bodies might increase the growth of U.S. and Europe atopic dermatitis market. For instance, in December 2016, The FDA approved Eucrisa (Crisaborole) ointment manufactured by Pfizer used in the treatment of mild to moderate eczema (atopic dermatitis) in patients with two years of age. The launch of new classes of drugs gives patients and healthcare professional’s alternatives to other classes of drugs such as corticosteroids, and calcineurin inhibitors.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/u-s-and-europe-atopic-dermatitis-market/#ulp-14mlyhjMGhVjZqa3

 

 

U.S. and Europe holds a dominant share in the global atopic dermatitis market. U.S. accounts for largest share followed by Europe. U.S. market growing at significant rate due to increase in the prevalence of atopic dermatitis (According to the National Eczema Association (NEA), atopic dermatitis affects nearly 10% to 20% of infants in the U.S.). Newer drug approvals, increase in healthcare expenditure, and revised reimbursement policies might increase the growth of atopic dermatitis market in U.S. Europe holds the second largest share in global atopic dermatitis market due to change in lifestyle, food habituations, development in research and drug development, and the development of healthcare infrastructure. The increase in the prevalence of allergic conditions (According to Allergo Journal International, 40.8 % of German adolescents and children were sensitized to a minimum of one food allergens or inhalants measured) in European region also increases the growth of Europe atopic dermatitis market.

 

Some of the players in U.S. and Europe atopic dermatitis market are Sanofi (France), Galderma SA (Nestle) (Switzerland), Allergan (U.S.), Novartis AG (Switzerland), Bristol-Myers Squibb (U.S.), Bayer AG (Germany), Otsuka Pharmaceutical Co., Ltd (Japan), Regeneron Pharmaceuticals (U.S.), Pfizer Inc. (U.S.), Encore Dermatology, Inc. (U.S.), Medimetriks Pharmaceuticals, Inc. (U.S.), and LEO Pharma A/S (Denmark), to name a few.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/u-s-and-europe-atopic-dermatitis-market/

 

 

About Precision Business Insights

 

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

 

Contact to Precision Business Insights,

 

Kemp House,

152 – 160 City Road,

London EC1V 2NX

 

Email: sales@precisionbusinessinsights.com

 

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.